中国医学前沿杂志(电子版)
中國醫學前沿雜誌(電子版)
중국의학전연잡지(전자판)
CHINESE JOURNAL OF THE FRONTIERS OF MEDICAL SCIENCE(ELECTRONIC VERSION)
2015年
4期
72-75
,共4页
魏从光%崔晓娜%王建业%孙杨
魏從光%崔曉娜%王建業%孫楊
위종광%최효나%왕건업%손양
氟哌噻吨美利曲辛片%埃索美拉唑%莫沙必利%慢性胃炎
氟哌噻噸美利麯辛片%埃索美拉唑%莫沙必利%慢性胃炎
불고새둔미리곡신편%애색미랍서%막사필리%만성위염
Flupentixol and melitracen tablets%Esomeprazole%Mosapride%Chronic gastritis
目的观察氟哌噻吨美利曲辛片联合埃索美拉唑、莫沙必利在女性慢性胃炎患者中的治疗效果,并对患者的焦虑和抑郁状态改善程度进行评分。方法选择2011年1月至2014年10月两院门诊及入院治疗的符合入组标准的118例女性慢性胃炎患者为研究对象,随机分为试验组(50例)和对照组(68例)。试验组患者给予氟哌噻吨美利曲辛片、埃索美拉唑镁肠溶片、枸橼酸莫沙必利分散片口服,对照组患者给予埃索美拉唑镁肠溶片和枸橼酸莫沙必利片口服。疗程均为4周。分别对患者治疗前后的胃肠道症状及焦虑、抑郁状态进行胃肠功能症状分级量表-C类(GSRS-C)、汉密尔顿焦虑量表(HAMA)和汉密尔顿抑郁量表(HAMD)量化评分。结果治疗后,两组患者胃肠道症状及焦虑、抑郁状态均较治疗前显著改善(P<0.05),且试验组较对照组改善效果更明显(P<0.05)。结论氟哌噻吨美利曲辛片联合埃索美拉唑、莫沙必利治疗女性慢性胃炎伴焦虑及抑郁症状,能够取得显著效果,患者胃肠道症状和焦虑、抑郁状态改善较明显,耐受性好。
目的觀察氟哌噻噸美利麯辛片聯閤埃索美拉唑、莫沙必利在女性慢性胃炎患者中的治療效果,併對患者的焦慮和抑鬱狀態改善程度進行評分。方法選擇2011年1月至2014年10月兩院門診及入院治療的符閤入組標準的118例女性慢性胃炎患者為研究對象,隨機分為試驗組(50例)和對照組(68例)。試驗組患者給予氟哌噻噸美利麯辛片、埃索美拉唑鎂腸溶片、枸櫞痠莫沙必利分散片口服,對照組患者給予埃索美拉唑鎂腸溶片和枸櫞痠莫沙必利片口服。療程均為4週。分彆對患者治療前後的胃腸道癥狀及焦慮、抑鬱狀態進行胃腸功能癥狀分級量錶-C類(GSRS-C)、漢密爾頓焦慮量錶(HAMA)和漢密爾頓抑鬱量錶(HAMD)量化評分。結果治療後,兩組患者胃腸道癥狀及焦慮、抑鬱狀態均較治療前顯著改善(P<0.05),且試驗組較對照組改善效果更明顯(P<0.05)。結論氟哌噻噸美利麯辛片聯閤埃索美拉唑、莫沙必利治療女性慢性胃炎伴焦慮及抑鬱癥狀,能夠取得顯著效果,患者胃腸道癥狀和焦慮、抑鬱狀態改善較明顯,耐受性好。
목적관찰불고새둔미리곡신편연합애색미랍서、막사필리재녀성만성위염환자중적치료효과,병대환자적초필화억욱상태개선정도진행평분。방법선택2011년1월지2014년10월량원문진급입원치료적부합입조표준적118례녀성만성위염환자위연구대상,수궤분위시험조(50례)화대조조(68례)。시험조환자급여불고새둔미리곡신편、애색미랍서미장용편、구연산막사필리분산편구복,대조조환자급여애색미랍서미장용편화구연산막사필리편구복。료정균위4주。분별대환자치료전후적위장도증상급초필、억욱상태진행위장공능증상분급량표-C류(GSRS-C)、한밀이돈초필량표(HAMA)화한밀이돈억욱량표(HAMD)양화평분。결과치료후,량조환자위장도증상급초필、억욱상태균교치료전현저개선(P<0.05),차시험조교대조조개선효과경명현(P<0.05)。결론불고새둔미리곡신편연합애색미랍서、막사필리치료녀성만성위염반초필급억욱증상,능구취득현저효과,환자위장도증상화초필、억욱상태개선교명현,내수성호。
Objective To discuss the clinical curative effect of lfupentixol and melitracen tablets combined with esomeprazole magnesium and mosapride on the treatment of women with chronic gastritis, and to discuss the intervention efifcacy on anxious and depressed mood of these patients. Method 118 cases famle patients with chronic gastritis outpatients and inpatients in our hospital were divided randomly into experimental group and control group from January 2011 to October 2014. The patients in experimental group members were given lfupentixol and melitracen tablets, esomeprazole and mosapride. The patients in control group were given esomeprazole and mosapride. The treatment lasted for 4 weeks. Pretherapy and post-treatment, patients were given the GSRS-C, HAMA and HAMD evaluation. Result The scores of the two groups were signiifcantly decreased than the beginning and experimental group's scores were significantly lower than control group (P < 0.05). Conclusion Flupentixol and melitracen tablets combined with esorneprazole magnesium and mosapride has a more significant clinical curative effect on the treatment of chronic gastritis patients with gastrointestinal symptoms, anxiety and depression can improved signiifcantly, well tolerated.